Context Therapeutics Inc. (NASDAQ:CNTX) is Great Point Partners LLC’s 9th Largest Position

Great Point Partners LLC trimmed its stake in Context Therapeutics Inc. (NASDAQ:CNTX) by 6.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,934,982 shares of the company’s stock after selling 484,373 shares during the quarter. Context Therapeutics accounts for 4.0% of Great Point Partners LLC’s portfolio, making the stock its 9th biggest holding. Great Point Partners LLC owned about 0.09% of Context Therapeutics worth $13,593,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of CNTX. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after purchasing an additional 25,300 shares during the last quarter. Opaleye Management Inc. raised its holdings in Context Therapeutics by 13.7% in the first quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after buying an additional 133,357 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares in the last quarter. Ally Bridge Group NY LLC lifted its stake in shares of Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after buying an additional 1,160,281 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Context Therapeutics during the second quarter valued at approximately $3,881,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on CNTX. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd. D. Boral Capital started coverage on Context Therapeutics in a research note on Monday. They issued a “buy” rating and a $9.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Context Therapeutics has a consensus rating of “Buy” and a consensus target price of $6.80.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $1.47 on Wednesday. Context Therapeutics Inc. has a 12-month low of $0.77 and a 12-month high of $2.75. The firm’s 50 day moving average is $1.97 and its 200 day moving average is $2.08.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, analysts predict that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.